HM
HealthCor Management Portfolio holdings
AUM
$109M
This Quarter Return
+8.39%
1 Year Return
+11.46%
3 Year Return
+50.01%
5 Year Return
+144.68%
10 Year Return
–
AUM
$2.47B
AUM Growth
+$2.47B
(+3.4%)
Cap. Flow
-$13.7M
Cap. Flow
% of AUM
-0.56%
Top 10 Holdings %
Top 10 Hldgs %
55.01%
Holding
63
New
13
Increased
17
Reduced
8
Closed
25
Top Buys
| 1 |
Zimmer Biomet
ZBH
|
$151M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$108M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$91.6M |
| 4 |
UnitedHealth
UNH
|
$87.8M |
| 5 |
Cooper Companies
COO
|
$81.4M |
Top Sells
| 1 |
Becton Dickinson
BDX
|
$145M |
| 2 |
Labcorp
LH
|
$92M |
| 3 |
Cigna
CI
|
$88.6M |
| 4 |
Encompass Health
EHC
|
$77.2M |
| 5 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$74.8M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Zimmer Biomet
ZBH
$21B
| $178M | 7.12% | 1,306,170 +1,107,820 | +559% | +$151M |
|
|
2
UnitedHealth
UNH
$281B
| $159M | 6.38% | 511,370 +281,720 | +123% | +$87.8M |
|
3
Medtronic
MDT
$119B
| $146M | 5.83% | 1,402,160 +486,720 | +53% | +$50.6M |
|
|
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $139M | 5.57% | 1,790,310 +1,389,270 | +346% | +$108M |
|
5
Madrigal Pharmaceuticals
MDGL
$9.76B
| $134M | 5.37% | 1,129,948 -67,936 | -6% | -$8.07M |
|
6
IQVIA
IQV
$32.4B
| $133M | 5.3% | 840,740 +295,950 | +54% | +$46.7M |
|
7
Aurinia Pharmaceuticals
AUPH
$1.58B
| $131M | 5.23% | 8,873,953 -627,445 | -7% | -$9.24M |
|
8
AbbVie
ABBV
$372B
| $116M | 4.62% | 1,318,900 +1,330 | +0.1% | +$116K |
|
9
HCA Healthcare
HCA
$94.5B
| $115M | 4.62% | 926,310 +125,020 | +16% | +$15.6M |
|
10
Regeneron Pharmaceuticals
REGN
$61.5B
| $107M | 4.26% | 190,310 +133,760 | +237% | +$74.9M |
|
|
NVRO
11
DELISTED
NEVRO CORP.
NVRO
| $102M | 4.08% | 730,977 -323,126 | -31% | -$45M |
|
|
12
Vertex Pharmaceuticals
VRTX
$100B
| $98.6M | 3.95% | 362,390 +336,770 | +1,314% | +$91.6M |
|
13
Humana
HUM
$36.5B
| $94.8M | 3.79% | 228,930 +159,380 | +229% | +$66M |
|
14
Guardant Health
GH
$8.41B
| $89.2M | 3.57% | 797,730 +78,890 | +11% | +$8.82M |
|
15
Neurocrine Biosciences
NBIX
$13.8B
| $89.1M | 3.57% | 927,070 +571,300 | +161% | +$54.9M |
|
|
16
Cooper Companies
COO
$13.4B
| $81.4M | 3.26% | +241,540 | New | +$81.4M |
|
17
Arcturus Therapeutics
ARCT
$462M
| $68.4M | 2.74% | 1,594,452 +1,500,252 | +1,593% | +$64.4M |
|
18
Royalty Pharma
RPRX
$15.6B
| $63M | 2.52% | 1,496,410 +580,060 | +63% | +$24.4M |
|
19
Amgen
AMGN
$155B
| $59.4M | 2.38% | 233,740 -25,460 | -10% | -$6.47M |
|
20
Teleflex
TFX
$5.59B
| $56.2M | 2.25% | +165,160 | New | +$56.2M |
|
21
Charles River Laboratories
CRL
$8.04B
| $54.9M | 2.2% | 242,230 +141,500 | +140% | +$32M |
|
22
Pediatrix Medical
MD
$1.5B
| $52.7M | 2.11% | 3,234,280 -153,685 | -5% | -$2.5M |
|
|
ARNA
23
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $43.2M | 1.73% | 578,030 +97,570 | +20% | +$7.3M |
|
24
Danaher
DHR
$147B
| $31.1M | 1.25% | 144,600 -232,065 | -62% | -$50M |
|
25
Tenet Healthcare
THC
$16.3B
| $27.3M | 1.09% | 1,114,980 +986,741 | +769% | +$24.2M |
|